Welcome to our dedicated page for Ocean Biomedical news (Ticker: OCEA), a resource for investors and traders seeking the latest updates and insights on Ocean Biomedical stock.
Ocean Biomedical, Inc. (symbol: OCEA) is a pioneering biopharmaceutical company focused on transforming basic research into groundbreaking clinical treatments. The company excels in partnering with inventor-scientists and premier research institutes to bridge the critical gap between laboratory discoveries and clinical applications. This unique approach aims to expedite the development of new medicines, ensuring that groundbreaking treatments reach the patients who need them most.
Ocean Biomedical is at the forefront of medical innovation, dedicating its resources to crucial areas of unmet medical needs. The company's operations span several key areas, including chronic hepatitis B and other serious diseases, where there is a significant demand for advanced therapeutic solutions.
In recent times, Ocean Biomedical has made notable strides in its projects and collaborations, enhancing its portfolio of potential treatments. For instance, the ongoing development of VRON-0200, in collaboration with Virion Therapeutics, showcases the company’s commitment to addressing chronic hepatitis B. Such initiatives not only enhance the company's market position but also underline its commitment to improving global health outcomes.
Financially, Ocean Biomedical has maintained a stable condition, driven by strategic partnerships and thoughtful financial planning. The company actively engages with investors and stakeholders through regular updates and transparent communication. For more information, the investor relations team can be reached at connect@oceanbiomedical.com.
Ocean Biomedical's significance in the biopharmaceutical industry cannot be overstated. By focusing on the translational process from research to clinical development, the company plays a vital role in the healthcare ecosystem. This holistic and patient-centric approach ensures that new medical discoveries are not just theoretical but are translated into viable treatments that can dramatically improve patient quality of life.
For more updates on Ocean Biomedical's latest news, projects, and collaborations, visit their official website at www.oceanbiomedical.com.
Ocean Biomedical (NASDAQ: OCEA) has announced breakthrough research findings showing their cancer immunotherapy candidates effectively interact with tyrosine kinase inhibitors (TKI) in treating non-small cell lung cancer (NSCLC). The research, published in Translational Oncology, demonstrates the therapy's ability to restore treatment sensitivity in osimertinib-resistant cases and suppress tumor growth when combined with TKI therapies.
The company's proprietary antibody suppresses CHi3L1 activity, leading to significant tumor reduction in preclinical models. Ocean Biomedical has also developed bispecific antibodies combining anti-CHI3L1 with anti-PD-1 or anti-CTLA4, showing efficacy in NSCLC, melanoma, and glioblastoma models.
The company plans to initiate preclinical studies and engage with the FDA this year for first-in-human trials. This development aligns with industry trends toward bispecific antibodies, highlighted by Merck's recent $588 million acquisition of LaNova's LM-299.
Ocean Biomedical (NASDAQ: OCEA) has announced significant advances in its malaria vaccine research program. The company's Scientific Co-founder, Dr. Jonathan Kurtis, has secured additional $3.5 million NIH funding and may benefit from new FDA guidance on lipid-encapsulated vaccines that could expedite development.
The research team has identified a unique protein called GARP on malaria-infected red blood cells, discovered through studies of children who naturally developed resistance to severe malaria. With a $4.6 million non-governmental Foundation grant, the team is currently testing three vaccine candidates in non-human primates.
The company aims to utilize lipid-encapsulated mRNA technology for vaccine delivery and plans to potentially initiate human trials by Q4 2025. The research focuses on blocking the malaria parasite's ability to enter and exit red blood cells, targeting a disease that claims over 500,000 children's lives annually in sub-Saharan Africa.
Ocean Biomedical (NASDAQ: OCEA) received a notice from Nasdaq on November 18, 2024, regarding non-compliance with listing rules due to failure to file its Q3 2024 Form 10-Q. This follows previous delays in filing its 2023 10-K and Q1/Q2 2024 10-Qs. While there's no immediate effect on stock listing, the company's securities are subject to delisting. A Nasdaq Hearings Panel will review the case on December 16, 2024. The company plans to file all delinquent reports as soon as possible.
Ocean Biomedical (NASDAQ: OCEA) announced receipt of a Nasdaq Staff Determination Letter on October 16, 2024. The letter states that the company failed to comply with Nasdaq's filing requirements as per Listing Rule 5250(c)(1). Specifically, Ocean Biomedical did not file its Form 10-K for the year ended December 31, 2024, and Forms 10-Q for the periods ended March 31, 2024, and June 30, 2024. Despite being granted an exception until October 14, 2024, to regain compliance, the company did not meet the terms. Ocean Biomedical will appeal this determination to a Hearings Panel as per Nasdaq Listing Rule 5800 Series procedures.
Ocean Biomedical (NASDAQ:OCEA) announced new research published in the Journal of Immunology by Scientific Co-founder Dr. Jack A. Elias and colleagues. The study expands understanding of how CHI3L1 inhibits the body's natural immune responses to lung cancers and related diseases like COPD. It demonstrates for the first time how CHI3L1 inhibits macrophage phagocytosis by stimulating two key phagocytosis checkpoint pathways.
The research suggests that CHI3L1-targeted therapeutics are promising interventions in cancer, COPD, and other disorders. Ocean Biomedical's monoclonal antibody is part of a unique oncology platform working to activate natural cancer immune responses by suppressing Chi3L1, with potential for broad application. The company has been granted patent allowance for multiple cancer types, including Prostate, Colon, Rectal, Ovarian, Kidney, Breast, Glioblastoma, Melanoma, and Lung Cancer.
Ocean Biomedical (NASDAQ:OCEA) announced a key U.S. patent issued for Dr. Jonathan Kurtis' groundbreaking malaria therapeutic antibody discovery targeting PfGARP. This patent expands protection for novel approaches to malaria prevention and treatment, including:
1. A powerful vaccine candidate for long-term prevention
2. A therapeutic antibody for short-term prevention
3. A small molecule drug to treat severe malaria
The patent adds to Ocean Biomedical's portfolio of over 60 patents developed through $125M in grants. This novel approach causes parasite death at a key stage in the malarial cycle, addressing growing resistance to current Artemisinin-based drugs. The company aims to develop new treatment options to combat malaria, which killed approximately 627,000 individuals in 2022.
Ocean Biomedical (NASDAQ: OCEA) has received a notice from Nasdaq due to its failure to file the Q2 2024 Form 10-Q on time. This non-compliance with Nasdaq Listing Rule 5250(c)(1) stems from previously disclosed issues related to the company's 2023 10-K filing. While there's no immediate impact on OCEA's stock listing or trading, the company must submit a compliance plan by September 3, 2024, and file the delinquent reports by October 14, 2024. These include the Q2 2024 10-Q, Q1 2024 10-Q, and 2023 10-K. Ocean Biomedical intends to file these reports as soon as possible. The situation highlights potential risks for investors, as continued delays could affect the stock's listing status.
Ocean Biomedical (NASDAQ: OCEA) congratulated its JV partner Virion Therapeutics on presenting successful Phase 1b data for VRON-0200, a novel immunotherapy aiming for an HBV functional cure, at EASL 2024 Congress.
The data showcased that VRON-0200, using glycoprotein D as a checkpoint modifier, is safe, well-tolerated, and immunogenic for chronic HBV patients after a single intramuscular injection. This treatment could stimulate T cell responses even in patients with little to no prior HBV immunity.
This development could support Virion's other pipeline programs, such as VRON-0300 for advanced tumors. The global chronic HBV treatment market is expected to reach $6.5 billion by 2032, reflecting the high demand for new treatments.
Ocean Biomedical (NASDAQ: OCEA) announced on May 30, 2024, that it received a notice from Nasdaq regarding the late filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2024. The company is currently not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filings with the SEC. This delay follows previous issues with filing its 10-K for the year ended December 31, 2023.
Nasdaq has required Ocean Biomedical to submit a compliance plan by June 14, 2024, and to file the delinquent Form 10-Q by October 14, 2024. The notice has no immediate impact on the listing or trading of Ocean Biomedical's stock, but further delays could affect its Nasdaq listing. The company aims to file the overdue report as soon as possible.
On May 16, 2024, Ocean Biomedical (NASDAQ: OCEA) announced a new patent for malaria therapeutic antibody discoveries by Dr. Jonathan Kurtis. These antibodies aim to prevent malaria infection and treat severe cases by inducing parasite death via apoptosis during a critical stage of the malaria cycle. This patent adds to Ocean Biomedical's global portfolio, particularly important as malaria strains show resistance to current Artemisinin-based treatments. Ocean is optimizing vaccine and therapeutic antibody formulations before IND submission and clinical trials. Malaria remains a leading cause of death, particularly among children, with 627,000 fatalities in 2022. The new patent strengthens Ocean Biomedical's efforts to address this unmet medical need, leveraging partnerships with top research institutions.
FAQ
What is the current stock price of Ocean Biomedical (OCEA)?
What is the market cap of Ocean Biomedical (OCEA)?
What does Ocean Biomedical, Inc. do?
What is the stock symbol for Ocean Biomedical, Inc.?
What are some recent projects of Ocean Biomedical?
How does Ocean Biomedical maintain its financial health?
Who are the key partners of Ocean Biomedical?
How can investors contact Ocean Biomedical?
What diseases does Ocean Biomedical focus on?
Where can I find more information about Ocean Biomedical's projects?
What is Ocean Biomedical's approach to clinical development?
Who is the Communications Director of Ocean Biomedical?
